Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 1
1996 2
1997 3
1998 4
1999 3
2000 2
2001 1
2002 6
2003 4
2004 9
2005 9
2006 4
2007 3
2008 5
2009 2
2010 11
2011 9
2012 15
2013 7
2014 7
2015 6
2016 4
2017 3
2018 1
2019 3
2020 1
2021 1
2023 1
2024 4
2025 4
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean frumberg d (38 results)?
International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data.
Turki AT, Fan Y, Hernández-Sánchez A, Silva W, Fleming S, Yalcin K, Van Elssen CHMJ, Madanat Y, Karasek M, Aljurf M, Della Porta MG, Martinez-Roca A, Guarnera L, Steffen K, Antoniou E, Rivas MM, Mishra DK, Blum AT, Manantsoa SN, Adiat A, Enshaei A, Thol F, Voso MT, Chen J, Elhassan TA, Moorman AV, Vidriales MB, Neuendorff NR, Koc A, Mishra P, Strumberg D, Fourmanov RS, Heine L, Kleesiek J, Munárriz D, Asti G, Mokoonlall M, Kometas M, Rego E, Mecklenbrauck R, Sobas M, Wu D, Nensa F, Engelke M. Turki AT, et al. Among authors: strumberg d. Nat Commun. 2026 Mar 20;17(1):2649. doi: 10.1038/s41467-026-70584-z. Nat Commun. 2026. PMID: 41856996 Free PMC article. Clinical Trial.
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators. Al-Sawaf O, et al. N Engl J Med. 2026 Mar 12;394(11):1084-1096. doi: 10.1056/NEJMoa2515458. Epub 2025 Dec 6. N Engl J Med. 2026. PMID: 41358601 Clinical Trial.
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Al-Sawaf O, Fürstenau M, Giza A, Robrecht S, von Tresckow J, Fink AM, Simon F, Tausch E, Schneider C, Sivcheva L, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Juliusson G, da Cunha-Bang C, Illmer T, Gregor M, Thornton P, Janssens A, Tadmor T, Lindström V, Staber P, Levin MD, Wendtner CM, Kreuzer KA, Ritgen M, Stilgenbauer S, Kater AP, Niemann C, Fischer K, Eichhorst B, Hallek M. Al-Sawaf O, et al. Among authors: strumberg d. Blood. 2025 Nov 13;146(20):2406-2416. doi: 10.1182/blood.2025028899. Blood. 2025. PMID: 40864973 Free PMC article.
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trial.
Dührsen U, Bockisch A, Hertenstein B, Karsten IE, Kroschinsky F, Heuser M, Hochhaus A, Höffkes HG, Behringer D, Prange-Krex G, Tometten M, Grieshammer M, Grigoleit GU, Schmalz O, Jordan K, Bernhard H, Gaska T, Giagounidis A, Schroers R, Martens UM, Held G, Klapper W, Jöckel KH, Nonnemacher M, Hüttmann A; PETAL Trial Investigators. Dührsen U, et al. Blood Neoplasia. 2024 May 21;1(3):100018. doi: 10.1016/j.bneo.2024.100018. eCollection 2024 Sep. Blood Neoplasia. 2024. PMID: 40453056 Free PMC article. Clinical Trial.
Prognosis and quality of life in patients with locally advanced rectal cancer after abdominoperineal resection in the CAO/ARO/AIO-04 randomized phase 3 trial.
Gaedcke J, Sahrhage M, Ebeling M, Azizian A, Rühlmann F, Bernhardt M, Grade M, Bechstein WO, Germer CT, Grützmann R, Piso P, Hofheinz RD, Staib L, Beißbarth T, Kosmala R, Fokas E, Rödel C, Ghadimi M; German Rectal Cancer Study Group. Gaedcke J, et al. Sci Rep. 2025 Feb 13;15(1):5401. doi: 10.1038/s41598-024-83105-z. Sci Rep. 2025. PMID: 39948076 Free PMC article. Clinical Trial.
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial.
Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H; German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators; German-speaking Myeloma Multicenter Group (GMMG) HD7. Mai EK, et al. J Clin Oncol. 2025 Apr 10;43(11):1279-1288. doi: 10.1200/JCO-24-02266. Epub 2024 Dec 9. J Clin Oncol. 2025. PMID: 39652594 Free PMC article. Clinical Trial.
The neuroepithelial origin of ovarian carcinomas explained through an epithelial-mesenchymal-ectodermal transition enhanced by cisplatin.
Díaz-Carballo D, Safoor A, Saka S, Noa-Bolaño A, D'Souza F, Klein J, Acikelli AH, Malak S, Rahner U, Turki AT, Höppner A, Kamitz A, Song W, Chen YG, Kamada L, Tannapfel A, Brinkmann S, Ochsenfarth C, Strumberg D. Díaz-Carballo D, et al. Among authors: strumberg d. Sci Rep. 2024 Nov 26;14(1):29286. doi: 10.1038/s41598-024-76984-9. Sci Rep. 2024. PMID: 39592661 Free PMC article.
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Sivchev L, Niemann CU, Schwarer A, Loscertales J, Weinkove R, Strumberg D, Kilfoyle A, Manzoor BS, Jawaid D, Emechebe N, Devine J, Boyer M, Runkel ED, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: strumberg d. Blood. 2024 Oct 31;144(18):1924-1935. doi: 10.1182/blood.2024024631. Blood. 2024. PMID: 39082668 Free PMC article. Clinical Trial.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Goetze TO, Hofheinz RD, Gaiser T, Schmalenberg H, Strumberg D, Goekkurt E, Angermeier S, Zander T, Kopp HG, Pink D, Siegler G, Schenk M, de Vita F, Galizia G, Maiello E, Bechstein WO, Elshafei M, Loose M, Sookthai D, Brulin T, Pauligk C, Homann N, Al-Batran SE. Goetze TO, et al. Among authors: strumberg d. Int J Cancer. 2023 Jul 1;153(1):153-163. doi: 10.1002/ijc.34495. Epub 2023 Mar 23. Int J Cancer. 2023. PMID: 36883420 Clinical Trial.
Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.
Díaz-Carballo D, Saka S, Acikelli AH, Homp E, Erwes J, Demmig R, Klein J, Schröer K, Malak S, D'Souza F, Noa-Bolaño A, Menze S, Pano E, Andrioff S, Teipel M, Dammann P, Klein D, Nasreen A, Tannapfel A, Grandi N, Tramontano E, Ochsenfarth C, Strumberg D. Díaz-Carballo D, et al. Among authors: strumberg d. Commun Biol. 2021 Mar 3;4(1):276. doi: 10.1038/s42003-021-01800-3. Commun Biol. 2021. PMID: 33658617 Free PMC article.
124 results